Brokerages forecast that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will report $31.00 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Arrowhead Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $20.00 million and the highest estimate coming in at $42.00 million. Arrowhead Pharmaceuticals posted sales of $34.66 million in the same quarter last year, which indicates a negative year over year growth rate of 10.6%. The company is expected to announce its next quarterly earnings results on Thursday, February 6th.
On average, analysts expect that Arrowhead Pharmaceuticals will report full-year sales of $86.87 million for the current fiscal year, with estimates ranging from $53.00 million to $128.00 million. For the next fiscal year, analysts anticipate that the firm will report sales of $75.08 million, with estimates ranging from $40.00 million to $116.30 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that cover Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Monday, November 25th. The biotechnology company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.03). The business had revenue of $43.29 million for the quarter, compared to analysts’ expectations of $36.97 million. Arrowhead Pharmaceuticals had a return on equity of 32.30% and a net margin of 40.27%.
Shares of ARWR opened at $67.77 on Tuesday. The company’s 50-day moving average price is $50.25 and its 200 day moving average price is $34.28. Arrowhead Pharmaceuticals has a 12-month low of $10.41 and a 12-month high of $73.72. The firm has a market cap of $6.44 billion, a P/E ratio of 98.22 and a beta of 1.98.
In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 4,250 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $29.00, for a total transaction of $123,250.00. Following the sale, the chief executive officer now directly owns 2,146,153 shares in the company, valued at $62,238,437. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael S. Perry sold 85,000 shares of the stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $30.00, for a total transaction of $2,550,000.00. Following the sale, the director now directly owns 121,000 shares in the company, valued at approximately $3,630,000. The disclosure for this sale can be found here. Insiders sold 288,071 shares of company stock valued at $10,518,443 over the last ninety days. Insiders own 4.80% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 96.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,020 shares of the biotechnology company’s stock worth $29,000 after buying an additional 500 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the second quarter worth $34,000. Moneta Group Investment Advisors LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at $368,000. Pearl River Capital LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at $111,000. Finally, Riverhead Capital Management LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at $148,000. Hedge funds and other institutional investors own 70.39% of the company’s stock.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.